Trends underlying early-stage drug discovery and development collaborations from October 2002 to September 2004
- PDF / 84,815 Bytes
- 5 Pages / 595 x 842 pts (A4) Page_size
- 33 Downloads / 166 Views
Marketspace Trends underlying early-stage drug discovery and development collaborations from October 2002 to September 2004 Mark J. Belsey and Alex K. Pavlou Date received (in revised form): 30th March, 2005
Abstract
Keywords: early-stage collaboration, licensing, lead optimisation, lead identification, target validation, drug discovery
As part of Datamonitor’s alliance and licensing strategic analysis, the authors have completed a two year survey of the trends underlying early-stage drug discovery and development collaborations between October 2002 and September 2004, which included 524 early-stage deals. Deal analysis shows that the leading pharma and biotech companies (fully integrated players) are the principal collaboration seekers, and that target and product innovation is driving the new wave of 21st century deals. These deals cover all phases of early-stage drug development, with lead product/target identification/validation accounting for the greatest proportion of collaborations. This represents a shift away from initial-stage collaborations, which are primarily focused on technologies such as genomics, as a result of the lack of tangible results that such technologies have delivered in the past. Following the continuously increasing demand for late-stage high-value products, the aim of the money and time invested in these early-stage collaborations is to reverse the pipeline productivity crisis currently affecting the industry’s leaders over the mid to long term.
INTRODUCTION
Alex Pavlou BSc, MSc, PhD Datamonitor plc, Charles House, 108–110 Finchley Road, London NW3 5JJ, UK Tel: +44 (0) 20 7675 7079 Fax: +44 (0) 20 7675 7500 E-mail: [email protected]
There is currently a crisis among the pharmaceutical industry as in-house organic R&D fails to generate a significant number of high-value products to drive company growth and replace sales generated by products approaching the end of their life cycle that are facing patent expiry and generic competition. Early-stage collaborations within the biopharma sector are vital in driving innovation evolution through therapeutic and technological diversification. Overall, early-stage deals can generally be split into licensing and coresearch and development deals. Alliance seekers/licensees are looking to
increase their exposure to novel technologies, drive up target and lead identification and boost early-stage drug development. In return, their collaboration partners/licensors are set to gain greater financial stability, validate their technology and accelerate product development and optimisation. With the industry shifting as a whole towards utilising licensing to solve poor in-house R&D productivity, high-value licensing deal targets are becoming increasingly expensive and difficult to locate. An alternative for these companies is therefore to enter into co-R&D collaborations with promising emerging biopharmaceutical companies, to gain
& HENRY STEWART PUBLICATIONS 1478-565X. J O U R N A L O F C O M M E R C I A L B I O T E C H N O L O G Y . VOL 11.
Data Loading...
